For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Niagen Bioscience Inc’s stock clocked out at $10.03, up 0.50% from its previous closing price of $9.98. In other words, the price has increased by $0.50 from its previous closing price. On the day, 0.84 million shares were traded. NAGE stock price reached its highest trading level at $10.3 during the session, while it also had its lowest trading level at $9.88.
Ratios:
To gain a deeper understanding of NAGE’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 38.31. For the most recent quarter (mrq), Quick Ratio is recorded 3.24 and its Current Ratio is at 3.88. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on May 27, 2025, initiated with a Buy rating and assigned the stock a target price of $13.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 07 ’25 when Lopez Carlos Luis bought 273 shares for $7.86 per share. The transaction valued at 2,146 led to the insider holds 2,251 shares of the business.
Jaksch Frank L Jr sold 37,161 shares of NAGE for $229,956 on Dec 13 ’24. The Director now owns 244,179 shares after completing the transaction at $6.19 per share. On Dec 13 ’24, another insider, Frank Jaksch Jr., who serves as the affiliate of the company, bought 37,161 shares for $6.19 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAGE now has a Market Capitalization of 799922560 and an Enterprise Value of 744567168. As of this moment, Niagen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 46.72, and their Forward P/E ratio for the next fiscal year is 36.88. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.87. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.88 while its Price-to-Book (P/B) ratio in mrq is 12.43. Its current Enterprise Value per Revenue stands at 6.402 whereas that against EBITDA is 42.664.
Stock Price History:
The Beta on a monthly basis for NAGE is 2.22, which has changed by 1.8739254 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, NAGE has reached a high of $14.69, while it has fallen to a 52-week low of $3.10. The 50-Day Moving Average of the stock is -9.81%, while the 200-Day Moving Average is calculated to be 21.43%.
Shares Statistics:
It appears that NAGE traded 1.10M shares on average per day over the past three months and 831070 shares per day over the past ten days. A total of 79.59M shares are outstanding, with a floating share count of 51.42M. Insiders hold about 35.52% of the company’s shares, while institutions hold 36.55% stake in the company. Shares short for NAGE as of 1753920000 were 3850928 with a Short Ratio of 3.49, compared to 1751241600 on 3578586. Therefore, it implies a Short% of Shares Outstanding of 3850928 and a Short% of Float of 7.33.
Earnings Estimates
Niagen Bioscience Inc (NAGE) is currently under the scrutiny of 2.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.02, with high estimates of $0.02 and low estimates of $0.02.
Analysts are recommending an EPS of between $0.15 and $0.13 for the fiscal current year, implying an average EPS of $0.14. EPS for the following year is $0.22, with 2.0 analysts recommending between $0.22 and $0.21.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $30.73M. It ranges from a high estimate of $31.5M to a low estimate of $29.6M. As of the current estimate, Niagen Bioscience Inc’s year-ago sales were $25.58MFor the next quarter, 5 analysts are estimating revenue of $33.69M. There is a high estimate of $34.4M for the next quarter, whereas the lowest estimate is $32.5M.
A total of 5 analysts have provided revenue estimates for NAGE’s current fiscal year. The highest revenue estimate was $126.66M, while the lowest revenue estimate was $125.5M, resulting in an average revenue estimate of $126M. In the same quarter a year ago, actual revenue was $99.6MBased on 4 analysts’ estimates, the company’s revenue will be $152.59M in the next fiscal year. The high estimate is $158M and the low estimate is $148.56M.
